Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans
March 15, 2022 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, March 15, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, has...
Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors
December 03, 2021 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month
October 18, 2021 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 18, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity
October 15, 2021 18:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced...
Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
October 12, 2021 18:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
September 27, 2021 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Sept. 27, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences to Present to Investors at the H.C. Wainwright 23rd Annual Investment Conference
September 13, 2021 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will...
Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences’ Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants
August 30, 2021 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Aug. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced...
Distinguished Scientific and Clinical Leader to Join Enochian BioSciences’ Hepatitis B Cure Scientific Advisory Board
August 23, 2021 10:18 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Aug. 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced...
Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer
July 20, 2021 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, July 20, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...